Susan Hays, ANP, Washington University Siteman Cancer Center
Advertisement
Articles by Susan Hays, ANP, Washington University Siteman Cancer Center
Advertisement
Latest Updated Articles
Management of Adverse Effects in R/R HER2+ mBCPublished: September 23rd 2020 | Updated:
FDA-approved Therapies for Relapsed/Refractory HER2+ mBCPublished: September 23rd 2020 | Updated:
Practical Management of Early Stage HER2+ Breast CancerPublished: September 23rd 2020 | Updated:
HER2-targeted Therapy: Routes of AdministrationPublished: September 23rd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Outcomes With Bridging Therapy Correlate With Cilta-Cel Efficacy, Safety in Multiple Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
5